Q-omics provides the consensus-scored BLZF1 profile across patient tissues and cancer cell-line models. BLZF1 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, BLZF1 is differentially expressed in 13, with the highest sampling consensus in THCA. Additionally, BLZF1 RNA expression shows 21,350 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRP, THCA, and ACC as cancer lineages where BLZF1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BLZF1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BLZF1 survival associations across molecular data types. BLZF1 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (5) and mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BLZF1 RNA expression–survival associations across cancer types. High BLZF1 expression shows unfavorable associations in KIRP, ACC, LGG, LIHC and LUAD, but favorable associations in KIRC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for BLZF1 RNA expression.
This table summarizes BLZF1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 6. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for BLZF1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BLZF1 shows lower tumor expression in THCA and KICH and higher tumor expression in LIHC, KIRC, LUAD and BRCA. The THCA box plot shows higher BLZF1 RNA expression in normal versus tumor tissue (log2 FC = −0.568, t-test p < 0.001).
This table shows molecular features associated with BLZF1 in patient tissues and cancer cell lines. In patient samples, BLZF1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, BLZF1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Leukemia.
